Immunovant, INC

Immunovant announced fourth quarter and fiscal year 2026 financial results, highlighting positive preliminary data for IMVT-1402 in rheumatoid arthritis and providing updates on its clinical pipeline.

Immunovant announced its fiscal third quarter 2025 financial results, highlighted by full enrollment in a key IMVT-1402 trial and a significant capital raise extending its cash runway.

Immunovant, Inc. successfully completed an underwritten public offering of 26.2 million shares of common stock, generating approximately $550 million in gross proceeds.

Immunovant, Inc. announced a $550 million common stock offering and provided updates on its IMVT-1402 and batoclimab clinical programs, including a delay in batoclimab TED study results.

Immunovant, Inc. announced the departure of its Chief Medical Officer, Dr. Michael Geffner, effective November 21, 2025, as part of an R&D leadership restructuring.

Immunovant announced its fiscal second quarter results, highlighting progress in IMVT-1402 development and a delay in batoclimab Phase 3 TED study readouts to early 2026.

Immunovant reports a strong cash position of nearly $1 billion following a recent equity offering, while advancing its lead asset IMVT-1402 into multiple registrational trials for autoimmune diseases.

Immunovant reports increased net loss in Q2 2025 as it accelerates development of its lead FcRn inhibitor, IMVT-1402, across multiple autoimmune indications.

Immunovant, Inc. reported increased net losses and cash burn in Q1 2025 as it significantly expanded its clinical pipeline for IMVT-1402, initiating multiple potentially registrational trials.

Immunovant's Q3 2025 report reveals a net loss of $111.1 million, alongside advancements in IMVT-1402 clinical programs.

Immunovant's Q2 2025 report highlights increased R&D spending as the company advances its IMVT-1402 clinical programs and provides updates on batoclimab trials.

Immunovant, a clinical-stage immunology company, announced its financial results for the quarter ended June 30, 2024, and provided an update on its clinical development programs, particularly for IMVT-1402.

Immunovant Inc. reported its annual results, highlighting the discontinuation of batoclimab development to concentrate on IMVT-1402, while also detailing ongoing clinical trials and financial performance.

Immunovant, a clinical-stage immunology company, reported significant progress in its pipeline, initiating multiple registrational trials for its potentially best-in-class FcRn inhibitor IMVT-1402 across several autoimmune indications, while also announcing positive Phase 3 results for batoclimab in Myasthenia Gravis.

Immunovant's 10-K filing highlights the company's strategic shift towards IMVT-1402, a novel anti-FcRn antibody, while continuing development of batoclimab.

Atul Pande, a Director of Immunovant, Inc., sold 1,500 shares of common stock on July 24, 2026 for $39.80 per share.

Tiago Girao, Chief Financial Officer of Immunovant, Inc., sold 6,798 shares of common stock on July 23, 2026 for $38.69 per share.

Jay S Stout, Chief Technology Officer of Immunovant, Inc., sold 2,857 shares of common stock on July 23, 2026 for $38.69 per share.

Immunovant's Chief Operating Officer, Melanie Gloria, sold company shares to cover tax obligations related to restricted stock unit vesting.

Immunovant, Inc. Chief Legal Officer Christopher Van Tuyl sold shares to cover tax obligations related to RSU vesting, a non-discretionary transaction.

Immunovant's Chief Technology Officer, Jay Stout, sold company shares to cover tax obligations related to vesting restricted stock units.

Immunovant, Inc. has announced its 2026 Annual Meeting of Stockholders, to be held virtually on September 2, 2026, to elect directors, ratify auditor selection, and vote on executive compensation.

Immunovant, Inc. has filed definitive additional materials related to its proxy statement with the U.S. Securities and Exchange Commission.

Immunovant, Inc. has released its definitive proxy statement for the 2025 Annual Meeting of Stockholders, outlining proposals for director elections, auditor ratification, and an advisory vote on executive compensation, while disclosing increased net losses and recent leadership changes.

Immunovant has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.

Immunovant will hold its 2024 Annual Meeting of Stockholders virtually on August 12, 2024, to vote on the election of directors, ratification of the independent auditor, and executive compensation.

Roivant Sciences Ltd. increased its beneficial ownership in Immunovant, Inc. to 55.9% by acquiring 16.67 million shares in a recent public offering.

Immunovant, Inc. announced the appointment of Eric Venker, M.D., President and Chief Operating Officer of Roivant Sciences, Inc., as its new Chief Executive Officer, effective April 21, 2025, as detailed in an amended Schedule 13D filing by major shareholder Roivant Sciences Ltd.

Roivant Sciences Ltd. has increased its beneficial ownership in Immunovant, Inc. to 56.9% through a $337 million private placement, providing capital for Immunovant's development pipeline and general corporate purposes.

FMR LLC and its affiliates, along with Abigail P. Johnson, have reported a beneficial ownership of 8.4% of Immunovant Inc.'s common stock as of September 30, 2025.

Deep Track Capital, along with its affiliates, has disclosed a beneficial ownership of 5.59% in Immunovant Inc., totaling 9.5 million shares of common stock.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, disclosing a continued beneficial ownership of 10.1% of Immunovant Inc.'s common stock as of February 28, 2025.